Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Growth Metrics
Income Statement
Others
Ratios

Skinvisible (SKVI) Change in Accured Expenses (2016 - 2025)

Skinvisible (SKVI) has disclosed Change in Accured Expenses for 16 consecutive years, with $97013.0 as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 133.32% to $97013.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $394676.0 through Dec 2025, down 6.1% year-over-year, with the annual reading at $394676.0 for FY2025, 6.1% down from the prior year.
  • Change in Accured Expenses hit $97013.0 in Q4 2025 for Skinvisible, up from $75504.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $490421.0 in Q3 2024 to a low of -$291120.0 in Q4 2024.
  • Historically, Change in Accured Expenses has averaged $84237.4 across 5 years, with a median of $92613.0 in 2022.
  • Biggest five-year swings in Change in Accured Expenses: skyrocketed 1479.14% in 2022 and later crashed 363.82% in 2024.
  • Year by year, Change in Accured Expenses stood at $5763.0 in 2021, then surged by 1479.14% to $91006.0 in 2022, then grew by 21.25% to $110349.0 in 2023, then plummeted by 363.82% to -$291120.0 in 2024, then skyrocketed by 133.32% to $97013.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for SKVI at $97013.0 in Q4 2025, $75504.0 in Q3 2025, and $121828.0 in Q2 2025.